What is the current valuation of the recombinant vaccines market in Italy as of 2024?

The overall market valuation was $10.8 Million in 2024. Read More

What is the projected market valuation for the Italy recombinant vaccines market by 2035?

The projected valuation for 2035 is $58.0 Million. Read More

What is the expected CAGR for the Italy recombinant vaccines market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 16.51%. Read More

Which companies are the key players in the Italy recombinant vaccines market?

Key players include Pfizer, Moderna, Novavax, Sanofi, GSK, Merck, Bavarian Nordic, AstraZeneca, and Takeda. Read More

What are the different types of recombinant vaccines available in the market?

The market includes subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines. Read More

How did the subunit recombinant vaccines perform in terms of valuation in 2024?

Subunit recombinant vaccines had a valuation of $3.24 Million in 2024. Read More

What is the valuation of attenuated recombinant vaccines projected for 2035?

Attenuated recombinant vaccines are projected to reach $23.0 Million by 2035. Read More

Which diseases are targeted by recombinant vaccines in Italy?

Diseases targeted include pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others. Read More

What was the valuation of the influenza vaccine segment in 2024?

The influenza vaccine segment had a valuation of $2.5 Million in 2024. Read More

What are the end-user segments for recombinant vaccines in Italy?

End-user segments include hospitals & clinics, pediatrics, adults, veterinary, poultry, livestock, and others. Read More

Italy Recombinant Vaccines Market

ID: MRFR/Pharma/54245-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

Italy Recombinant Vaccines Market Research Report: By Product (Subunit Recombinant, Attenuated Recombinant Vaccines), By Disease (Cancer, Pneumococcal Disease, Hepatitis B, DPT) andBy End-Users (Pediatrics, Adults, Veterinary) - Growth & Industry Forecast 2025 To 2035

Italy Recombinant Vaccines Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 Subunit recombinant vaccines
  2. 4.1.2 Attenuated recombinant vaccines
  3. 4.1.3 Vector recombinant vaccines
2. 4.2 Life Sciences, BY Disease (USD Million)
  1. 4.2.1 Pneumococcal Disease
  2. 4.2.2 Cancer
  3. 4.2.3 Hepatitis B
  4. 4.2.4 Influenza
  5. 4.2.5 DPT
  6. 4.2.6 Others
3. 4.3 Life Sciences, BY End-User (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Pediatrics
  3. 4.3.3 Adults
  4. 4.3.4 Veterinary
  5. 4.3.5 Poultry
  6. 4.3.6 Livestock
  7. 4.3.7 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Moderna (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novavax (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 GSK (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bavarian Nordic (DK)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Takeda (JP)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY TYPE
3. 6.3 ITALY MARKET ANALYSIS BY DISEASE
4. 6.4 ITALY MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF LIFE SCIENCES
8. 6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
9. 6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
11. 6.11 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 LIFE SCIENCES, BY DISEASE, 2024 (% SHARE)
14. 6.14 LIFE SCIENCES, BY DISEASE, 2024 TO 2035 (USD Million)
15. 6.15 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
16. 6.16 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Life Sciences Market Segmentation

Life Sciences By Type (USD Million, 2025-2035)

Subunit recombinant vaccines
Attenuated recombinant vaccines
Vector recombinant vaccines

Life Sciences By Disease (USD Million, 2025-2035)

Pneumococcal Disease
Cancer
Hepatitis B
Influenza
DPT
Others

Life Sciences By End-User (USD Million, 2025-2035)

Hospitals & Clinics
Pediatrics
Adults
Veterinary
Poultry
Livestock
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”